Dendrimer pharmaceutical company Starpharma said on Tuesday that SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the highly transmissible Delta variant of SARS-CoV-2, reducing virus infectivity by> 99.99% after 30 seconds of exposure, based on new antiviral tests.
SPL7013 has been shown to be virucidal against the four variants of the SARS-CoV-2 coronavirus of concern: Alpha, Beta, Gamma and Delta. The broad-spectrum antiviral activity of SPL7013 has been demonstrated against multiple respiratory viruses, including influenza and RSV, as well as its consistent and potent activity against multiple variants of SARS-CoV-2.
Antiviral testing of SPL7013 was carried out in the laboratory of virologist Professor Philippe Gallay at the Scripps Research Institute, USA.
The infectious virus reduction percentages was reportedly achieved with 10 mg / mL of SPL7013 (the concentration in VIRALEZE). The Delta variant has been reported to be approximately 60% more transmissible than the Alpha variant, which is already highly infectious and is currently the most common variant in India and the UK, where it accounts for more than 90% of new cases.
Additionally, the VIRALEZE antiviral nasal spray is registered for sale in Europe and India and is available in select online markets, concluded the company.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib